Show simple item record

Files in this item


Item metadata

dc.contributor.authorLindsay, Colin R
dc.contributor.authorShaw, Emily C
dc.contributor.authorBlackhall, Fiona
dc.contributor.authorBlyth, Kevin G
dc.contributor.authorBrenton, James D
dc.contributor.authorChaturvedi, Anshuman
dc.contributor.authorClarke, Noel
dc.contributor.authorDick, Craig
dc.contributor.authorEvans, Thomas R J
dc.contributor.authorHall, Geoff
dc.contributor.authorHanby, Andrew M
dc.contributor.authorHarrison, David J
dc.contributor.authorJohnston, Stephen R D
dc.contributor.authorMason, Malcolm D
dc.contributor.authorMorton, Dion
dc.contributor.authorNewton-Bishop, Julia
dc.contributor.authorNicholson, Andrew G
dc.contributor.authorOien, Karin A
dc.contributor.authorPopat, Sanjay
dc.contributor.authorRassl, Doris
dc.contributor.authorSharpe, Rowena
dc.contributor.authorTaniere, Phillipe
dc.contributor.authorWalker, Ian
dc.contributor.authorWallace, William A
dc.contributor.authorWest, Nicholas P
dc.contributor.authorButler, Rachel
dc.contributor.authorGonzalez de Castro, David
dc.contributor.authorGriffiths, Mike
dc.contributor.authorJohnson, Peter W M
dc.identifier.citationLindsay , C R , Shaw , E C , Blackhall , F , Blyth , K G , Brenton , J D , Chaturvedi , A , Clarke , N , Dick , C , Evans , T R J , Hall , G , Hanby , A M , Harrison , D J , Johnston , S R D , Mason , M D , Morton , D , Newton-Bishop , J , Nicholson , A G , Oien , K A , Popat , S , Rassl , D , Sharpe , R , Taniere , P , Walker , I , Wallace , W A , West , N P , Butler , R , Gonzalez de Castro , D , Griffiths , M & Johnson , P W M 2018 , ' Somatic cancer genetics in the UK : real-world data from phase I of the Cancer Research UK Stratified Medicine Programme ' , ESMO Open , vol. 3 , no. 6 , e000408 .
dc.identifier.otherPURE: 256072498
dc.identifier.otherPURE UUID: ef49c148-f4f4-4055-9f2d-0892231ff68f
dc.identifier.otherPubMed: 30233821
dc.identifier.otherPubMedCentral: PMC6135448
dc.identifier.otherScopus: 85054552849
dc.identifier.otherORCID: /0000-0001-9041-9988/work/64034303
dc.identifier.otherWOS: 000495996200005
dc.descriptionThis study was supported by Cancer Research UK, AstraZeneca and Pfizer UK.en
dc.description.abstractIntroduction: Phase I of the Cancer Research UK Stratified Medicine Programme (SMP1) was designed to roll out molecular pathology testing nationwide at the point of cancer diagnosis, as well as facilitate an infrastructure where surplus cancer tissue could be used for research. It offered a non-trial setting to examine common UK cancer genetics in a real-world context. Methods: A total of 26 sites in England, Wales and Scotland, recruited samples from 7814 patients for genetic examination between 2011 and 2013. Tumour types involved were breast, colorectal, lung, prostate, ovarian cancer and malignant melanoma. Centralised molecular testing of surplus material from resections or biopsies of primary/metastatic tissue was performed, with samples examined for 3-5 genetic alterations deemed to be of key interest in site-specific cancers by the National Cancer Research Institute Clinical Study groups. Results: 10 754 patients (98% of those approached) consented to participate, from which 7814 tumour samples were genetically analysed. In total, 53% had at least one genetic aberration detected. From 1885 patients with lung cancer, KRAS mutation was noted to be highly prevalent in adenocarcinoma (37%). In breast cancer (1873 patients), there was a striking contrast in TP53 mutation incidence between patients with ductal cancer (27.3%) and lobular cancer (3.4%). Vast inter-tumour heterogeneity of colorectal cancer (1550 patients) was observed, including myriad double and triple combinations of genetic aberrations. Significant losses of important clinical information included smoking status in lung cancer and loss of distinction between low-grade and high-grade serous ovarian cancers. Conclusion: Nationwide molecular pathology testing in a non-trial setting is feasible. The experience with SMP1 has been used to inform ongoing CRUK flagship programmes such as the CRUK National Lung MATRIX trial and TRACERx.
dc.relation.ispartofESMO Openen
dc.rightsCopyright © Author(s) 2018. Open Access article. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, any changes made are indicated, and the use is non-commercial. See:
dc.subjectRC0254 Neoplasms. Tumors. Oncology (including Cancer)en
dc.subjectSDG 3 - Good Health and Well-beingen
dc.titleSomatic cancer genetics in the UK : real-world data from phase I of the Cancer Research UK Stratified Medicine Programmeen
dc.typeJournal articleen
dc.description.versionPublisher PDFen
dc.contributor.institutionUniversity of St Andrews. School of Medicineen
dc.contributor.institutionUniversity of St Andrews. Cellular Medicine Divisionen
dc.description.statusPeer revieweden

This item appears in the following Collection(s)

Show simple item record